WHO ICTRP trial
Prevention of weight gain when starting insulin therapy in patients with type 2…
NL-OMON20833 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON20833 |
|---|---|
| Public title | Prevention of weight gain when starting insulin therapy in patients with type 2 diabetes. |
| Scientific title | Prevention of insulin induced weight gain in type 2 diabetes: Cognitive behavioural therapy versus Liraglutide. |
| Primary sponsor | Erasmus Medical Center |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Conditions | type 2 diabetes, insulin therapy, adults, overweight, obesity, weight, glyceamic control, blood glucose, lifestyle, diabetes self management, cognitive behavioral therapy, liraglutide, GLP-1 type 2 diabetes, insuline therapie, volwassenen… |
| Interventions | The interventions are 26 weeks liraglutide or 26 weeks cognitive behavioral therapy added to insulin therapy and usual care. Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) analog that provides glycemic control and avoids… |
| Registration date | Mar 8, 2011 |
| Target size | 118 |
| Secondary IDs | NL2670;NTR2798; : ;ISRCTN wordt niet meer aangevraagd. |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: